Brief: Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data For ONCT-216 In Patients With Relapsed/Refractory Ewing Sarcoma At Ctos 2021 Virtual Annual Meeting
15/11/2021 14:28
Nov 15 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS PRESENTED UPDATED INTERIM PHASE 1/2
CLINICAL TRIAL DATA FOR ONCT-216 IN PATIENTS WITH
RELAPSED/REFRACTORY EWING SARCOMA AT CTOS 2021 VIRTUAL ANNUAL
MEETING
Source text for Eikon: ID:nGNX77s5Xm
Further company coverage: ONCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;